scPharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCPH research report →
Companywww.scpharmaceuticals.com
scPharmaceuticals Inc. , a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.
- CEO
- John H. Tucker
- IPO
- 2017
- Employees
- 162
- HQ
- Burlington, MA, US
Price Chart
Valuation
- Market Cap
- $302.20M
- P/E
- -5.38
- P/S
- 7.57
- P/B
- -14.29
- EV/EBITDA
- -6.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 68.84%
- Op Margin
- -121.16%
- Net Margin
- -141.73%
- ROE
- 1294.16%
- ROIC
- -80.54%
Growth & Income
- Revenue
- $36.33M · 167.28%
- Net Income
- $-85,148,000 · -55.35%
- EPS
- $-1.91 · -34.51%
- Op Income
- $-64,776,000
- FCF YoY
- -19.02%
Performance & Tape
- 52W High
- $6.28
- 52W Low
- $1.94
- 50D MA
- $5.34
- 200D MA
- $3.86
- Beta
- 0.30
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on SCPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 25 | SCHAEFFER LEONARD D | other | 43,104 |
| Oct 7, 25 | SCHAEFFER LEONARD D | sell | 19,750 |
| Oct 7, 25 | SCHAEFFER LEONARD D | sell | 30,000 |
| Oct 7, 25 | SCHAEFFER LEONARD D | sell | 16,300 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 30,000 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 19,750 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 6,124 |
| Oct 7, 25 | VEITINGER KLAUS R DR | sell | 16,300 |
| Oct 7, 25 | Abraham William Tober | sell | 19,750 |
| Oct 7, 25 | Abraham William Tober | sell | 16,300 |
Our SCPH Coverage
We haven't published any research on SCPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCPH Report →